Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants

abstract

In July 2014, the Committee on Infectious Diseases (COID) updated their guidance on the use of palivizumab, recommending against use in preterm infants 29 to 35 weeks' gestational age (wGA). A primary data source cited to support this significant change was the low respiratory syncytial virus (RSV) hospitalization rate observed in the subpopulation of preterm (<37 wGA) infants evaluated from 2000 to 2005 through the New Vaccine Surveillance Network (NVSN). Here we critically appraise the preterm infant data from the NVSN in the context of data regarding the use of palivizumab in this same time period. Data from the NVSN, an analysis of Florida Medicaid data, and a national survey of US in-hospital palivizumab administration demonstrated that during 2001 to 2007, palivizumab was administered to 59% to 83% of preterm infants born at <32 wGA and 21% to 27% of all preterm infants (<37 wGA). When the NVSN data regarding incidence of RSV hospitalization in preterm infant subgroups were evaluated as a function of chronologic age, preterm infants <32 wGA showed a paradoxical increase in RSV hospitalization with older age, with the highest risk of RSV hospitalization occurring at 18 to 23 months of age. This pattern is most consistent with a reduction in RSV hospitalizations in <32 wGA infants in the first 12 to 18 months of life due to high palivizumab use at these young ages. The NVSN data were not designed to and cannot accurately describe RSV disease burden in preterm infants given the small size of the analyzed subpopulation and the high use of palivizumab during the study period.

Keywords:

• palivizumab
• preterm
• NVSN
• RSV
• RSV hospitalization

Disclosure of potential conflicts of interest

JPD reports grants and other from AstraZeneca during the conduct of the study, grants and other from Gilead Sciences, grants from Alnylam Pharmaceuticals, grants and other from Microdose Therapeutx-Teva Pharmaceuticals, grants and other from Janssen Pharma, grants and other from ADMA Biologics, grants and other from Alios Biopharma and Janssen, and grants and other from Pulmocide outside the submitted work. CSA and DM are employees of AstraZeneca (Gaithersburg, MD). LPW has nothing to disclose.

Acknowledgments

Editorial assistance was provided by Anny Wu, PharmD, and Candace Lundin, DVM, MS, of Complete Healthcare Communications, Inc. (Chadds Ford, PA), funded by AstraZeneca (Gaithersburg, MD).

Funding

Sources of support: AstraZeneca (Gaithersburg, MD).